Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308547 | 0.78 | HDAC3 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL4306176 | 0.78 | HDAC3 (0.40) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL4309821 | 0.76 | HDAC3 (0.38) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL16566459 | 0.70 | HDAC6 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1365585 | 0.69 | HDAC6 (0.46) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1366117 | 0.67 | HDAC1 (0.45) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL2143881 | 0.63 | HDAC3 (0.40) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1368270 | 0.63 | HDAC6 (0.55) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL11963004 | 0.63 | HDAC6 (0.46) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1366004 | 0.63 | HDAC6 (0.46) | HDAC6HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009137503-A1 | HDAC INHIBITORS AND USES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| EP-2049483-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-04-22 | — | — | EP | claimed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | claimed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| EP-2691099-A1 | METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATION | Envivo Pharmaceuticals, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012135097-A1 | METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATION | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| WO-2009137503-A1 | HDAC INHIBITORS AND USES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2049483-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |